KIMYRSA (oritavancin)
Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
ApprovedActive
Key Facts
Indication
Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Phase
Approved
Status
Active
Company
About Melinta Therapeutics
Melinta Therapeutics is a commercial-stage antibiotic company confronting the global public health threat of antimicrobial resistance (AMR). Founded in 2000, the company has navigated significant financial challenges, including a Chapter 11 restructuring in 2019, to maintain a portfolio of vital anti-infective agents. Its strategy centers on commercializing its approved products—BAXDELA (delafloxacin), KIMYRSA (oritavancin), MINOCYCLINE Injection, and VABOMERE (meropenem and vaborbactam)—while advancing its pipeline. The company operates in a high-need but commercially difficult market, reliant on strategic partnerships and public health initiatives for sustainable success.
View full company profileTherapeutic Areas
Other Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Drugs
| Drug | Company | Phase |
|---|---|---|
| HY001 (ABSSSI program) | Helperby Therapeutics | Phase 3 (planned) |